Clinically validated.
Scientifically grounded.

Qvintip® is built on a strong clinical foundation and has been evaluated in collaboration with leading academic institutions, including the Cytological Laboratory at Uppsala University Hospital in Sweden. Ongoing collaboration with researchers remain a cornerstone of our work.

To date, Qvintip has been evaluated in more than 25 clinical studies over two decades, involving over 110,000 women across multiple countries. We continue to participate in clinical research on an ongoing basis.

Selected studies referenced below.

- Pereira, S et al. “Addressing Cervical Cancer Screening Through Self-Sampling and HPV Testing Among Under-Screened Women: A Case Study in the Decentralized Portuguese Setting” (2024). openRxiv. https://doi.org/10.1101/2024.04.05.24305323
- Latsuzbaia, Ardashel et al. “Comparison of the Clinical Accuracy of Xpert HPV Assay on Vaginal Self-Samples and Cervical Clinician-Taken Samples within the VALHUDES Framework.” The Journal of molecular diagnostics : JMD vol. 25,9 (2023): 702-708. doi:10.1016/j.jmoldx.2023.06.004
- Latsuzbaia, Ardashel et al. “Clinical Accuracy of Alinity m HR HPV Assay on Self- versus Clinician-Taken Samples Using the VALHUDES Protocol.” The Journal of molecular diagnostics : JMD vol. 25,12 (2023): 957-966. doi:10.1016/j.jmoldx.2023.09.008
- Bokan, Teodora et al. “Long term results of follow-up after HPV self-sampling with devices Qvintip and HerSwab in women non-attending cervical screening programme.” Radiology and oncology vol. 55,2 187-195. 6 Jan. 2021, doi:10.2478/raon-2021-0001
- Cadman, Louise et al. “A Randomized Comparison of Different Vaginal Self-sampling Devices and Urine for Human Papillomavirus Testing-Predictors 5.1.” Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 30,4 (2021): 661-668. doi:10.1158/1055-9965.EPI-20-1226
Bishop, Erin et al. “Acceptability of Human Papillomavirus Self-Sampling Among a National Sample of Women in the United States.” BioResearch open access vol. 8,1 65-73. 30 Apr. 2019, doi:10.1089/biores.2018.0040
- Jentschke, M et al. “Direct comparison of two vaginal self-sampling devices for the detection of human papillomavirus infections.” Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology vol. 82 (2016): 46-50. doi:10.1016/j.jcv.2016.06.016
- Gyllensten, U et al. “Short-time repeat high-risk HPV testing by self-sampling for screening of cervical cancer.” British journal of cancer vol. 105,5 (2011): 694-7. doi:10.1038/bjc.2011.277
- Wikström, I et al. “Self-sampling and HPV testing or ordinary Pap-smear in women not regularly attending screening: a randomised study.” British journal of cancer vol. 105,3 (2011): 337-9. doi:10.1038/bjc.2011.236
- Sanner, K et al. “Self-sampling of the vaginal fluid at home combined with high-risk HPV testing.” British journal of cancer vol. 101,5 (2009): 871-4. doi:10.1038/sj.bjc.6605194

Clinically validated. Scientifically grounded.

Aprovix

Clinically validated.
Scientifically grounded.